MIN/Sp/AU/CAMH3/6 TB Page 24 For the treatment of drug resistant TB, of the 26 countries that reported at least a case of MDR or XDR-TB during 2007, only 17 countries (65.4%) have an organized treatment programme. Even then, except for those supported through the GLC, not all patients have access to second line anti-TB drugs. As of January 2008, only 9 countries 34 had applied and been approved to access concessionary priced second line drugs from the Green Light Committee (GLC) of the Stop TB Partnership. This facility is available to all DOTS based TB Control programmes and should be utilized more widely than is currently the case considering the wide spread existence especially of MDR-TB cases. 4.4: Resource Mobilization 4.4.1 National financing of TB services During 2006, 39 of the 46 Member States (84.7%) % provided information on Financing TB Control 35 . These countries represent 93% of estimated TB incidence in the Region for that year. TB specific disaggregated data mobilized at national level is however not readily available as most programmes are implemented within primary health care services. WHO has since developed a planning and budgeting tool that is designed to help countries align their strategic plans and budgets with all the elements of the new Stop TB Strategy. During 2007, 35 countries in the African Region were introduced to the tool and used it to elaborate programme budgets. This is expected to improve the process of budget estimation and expenditure accountability in the coming years. 4.4.2 External financing of TB services During the past five years, external funding for TB control activities has increased significantly. The Global Fund to Fight AIDS, TB and Malaria (GFATM) has been the single most important source. During rounds 1-7 from 2002-2007, approximately 953 million USD (37% of total available grants global) was approved for TB Control activities in the African Region. This is the largest proportion, followed only by the West Pacific Region at 430 Million USD (Figure 4.7.1) 36 . Notwithstanding, this has not been marched with spending (Table 4.7.1) and translating into increased case detection and treatment success rates. 34 Burkina Faso, DRC, Guinea Conakry, Kenya, Lesotho, Mozambique, Rwanda, Tanzania (preapproval stage) and Uganda 35 WHO Global TB Control Report 2008 36 Adopted from WHO Global TB Control Report 2008